LiDCO Group PLC - Preliminary Results
for the Year Ended 31 December 2002
26-03-2003
LiDCO Group Plc ("LiDCO" or "the company"), the UK-based AIM-traded
cardiovascular monitoring company, announces its results for
the year to 31 December 2002.
Highlights
- Turnover increased by 81% to £2.04m (2001: £1.13m);
- Strong clinical acceptance of the technology demonstrated
by sensor usage trebling compared with 2001;
- Commercial validation of the business model evidenced
by 300 PulseCO and LiDCO Systems sold during 2002 (2001:
128 units);
- Lithium chloride injectate approved in principle for use
in Europe in January 2003, enabling commercialisation of
the LiDCOplus system across Europe in 2003;
- LiDCOplus system approved by US Food and Drug Administration
in January 2003; and
- Discussions have commenced with potential US distribution
partners to maximise access to the US market.
Notes for Editors
LiDCO researches, develops and sells innovative medical devices,
primarily for critical care and cardiovascular risk hospital
patients who require real-time minimally invasive cardiovascular
monitoring. The Group currently has two principal products,
both of which are patent protected, the LiDCOplus monitor
(a cardiovascular monitor displaying on a PC hardware platform
the real-time parameters of: fluid volume status, cardiac
output and oxygen delivery) and the LiDCO System (sensor and
disposables) which is used for the calibration of the monitor.
The Group's principal customers are hospitals.
LiDCO was founded in 1991 by Doctors Terry O'Brien (the current
CEO), David Band (the current Scientific Director), Robert
Linton and Jiri Kratochvil and by King's College, London.
LiDCO's head office is in London N1, whilst its sales offices
are located in the Granta Science Park, Cambridge and in Dallas,
Texas.
|
